

## Review Article

# Pulmonary complications after intrathecal morphine administration: a systematic review and meta-analysis with meta-regression and trial sequential analysis

Kariem El-Boghdady,  Yves Renard,  Jean-Benoit Rossel,  Eleni Moka,   
Thomas Volk,  Narinder Rawal, Cécile Jaques,  Marta Szyszko and Eric Albrecht 

## Summary

**Introduction** Intrathecal morphine provides effective postoperative analgesia, but there are concerns about potential pulmonary complications influencing peri-operative management. We aimed to determine whether there is an association between intrathecal morphine administration and pulmonary complications after non-obstetric surgery. We also aimed to determine whether there was a dose-dependent effect on pulmonary complications.

**Methods** We searched the literature systematically for randomised controlled trials comparing intrathecal morphine vs. control in patients undergoing any type of non-obstetric surgery under general or spinal anaesthesia. Primary outcomes were rates of postoperative sedation, respiratory depression and hypoxaemia. We performed a meta-analysis and meta-regression for each of our outcomes of interest and conducted trial sequential analysis to assess whether the required information size was achieved.

**Results** We included 127 trials (7388 patients). Rates of sedation and hypoxaemia were not increased significantly in patients receiving intrathecal morphine (odds ratio 1.00, 95%CI 0.78–1.28,  $p = 0.98$ , moderate quality evidence; and 1.22, 95%CI 0.84–1.79,  $p = 0.30$ , moderate quality evidence, respectively). There were more episodes of respiratory depression in patients receiving intrathecal morphine than control (odds ratio 1.78, 95%CI 1.19–2.67,  $p = 0.005$ , very low-quality evidence), which was no longer significant when morphine doses  $> 500 \mu\text{g}$  were not included (odds ratio 1.49, 95%CI 0.99–2.23,  $p = 0.06$ ). Meta-regression revealed associations between dose and rate of sedation, respiratory depression and hypoxaemia, but when doses of  $> 500 \mu\text{g}$  were not included, these associations did not persist. Trial sequential analyses suggest that further data may still be required for all outcomes, but statistical significance was reached for respiratory depression.

**Discussion** There is moderate evidence that intrathecal morphine does not increase rates of sedation or hypoxaemia after non-obstetric surgery. There is very low-quality evidence that intrathecal morphine might increase the rate of respiratory depression.

For full author affiliations, see end of article

Correspondence to: Eric Albrecht

Email: [eric.albrecht@chuv.ch](mailto:eric.albrecht@chuv.ch)

Accepted: 2 March 2025

Keywords: adverse effects; analgesia; intrathecal; opioids; postoperative pain; safety

X: [@elboghdady](#); [@DrEAlbrecht](#)

## Introduction

Intrathecal morphine has a long history of peri-operative use in a wide range of surgical settings [1, 2]. The favourable efficacy profile achieved with this single-injection technique includes reduced pain; decreased analgesic requirement; improved quality of spinal anaesthesia; and improved mobilisation after surgery [3]. This has led to generalised implementation of this modality, particularly in lower limb arthroplasty [4] and abdominal surgery settings [5].

Despite the well-described benefits, intrathecal morphine is associated with several adverse effects [6] including nausea; vomiting; pruritus; and urinary retention [1, 7]. However, the most significant adverse consequences of intrathecal morphine are pulmonary complications such as sedation; respiratory depression; and hypoxaemia [8, 9], the incidences of which are variable and multifactorial [10, 11]. It also remains unclear if there are any dose-dependent respiratory consequences of intrathecal morphine. This uncertainty has led to significant variations in clinical practice, particularly with respect to postoperative monitoring. Peri-operative management ranges from no additional monitoring following administration to admission to a high-dependency unit bed [12–14]. Thus, synthesising the literature is an important step to standardise practice with such significant resource implications.

We performed a systematic review and meta-analysis with meta-regression aiming to assess any association between doses of intrathecal morphine and rates of pulmonary complications after all types of non-obstetric surgery. We also aimed to define any potential threshold dose for each of the above-mentioned pulmonary complications.

## Methods

This study was conducted according to PRISMA guidelines [15]. A medical librarian searched MEDLINE, Embase, Cochrane Central Register of Controlled Clinical Trials, Wiley, [clinicaltrials.gov](https://www.clinicaltrials.gov) and Google Scholar (search limited to the first 300 results) on 4 May 2023 (online Supporting Information Appendix S1). The searches were reviewed by another medical librarian in accordance with the peer review of electronic search strategies checklist [16]. No language or date limits were placed on the search. References were imported into EndNote™ 20 software (Clarivate™, London, UK) for deduplication. In addition, we examined the references of all retrieved articles for any applicable trials that might not have been captured by the above approach. We sought randomised controlled trials involving adult patients (aged > 18 y) having elective

surgery who received intrathecal morphine compared with no intrathecal opioids. To be eligible, trials had to include any of the following outcomes of interest that we defined as primary in our review: sedation; respiratory depression; or hypoxaemia. Additional outcomes recorded were the need for additional oxygen therapy; the need for opioid antagonist administration (because of sedation, respiratory depression or hypoxaemia); or the need for any additional respiratory support or escalated levels of care or mortality.

Following deduplication, title, abstract and full-text screening were performed using Rayyan (Qatar Computing Research Institute, Doha, Qatar) by two independent reviewers, with a third adjudicating in case of disagreement. Data were then extracted into a Microsoft Excel spreadsheet (Microsoft Inc., Redmond, WA, USA), which was piloted before use. Data extracted included study details; patient characteristics; intervention information; and outcomes of interest. Text, tables or images from the source articles were evaluated to extract the number of participants and the number of events. Graphically presented data were extracted with plot digitising software (Plot Digitizer Version 2.1, Free Software Foundation, Boston, MA, USA). Where data were missing, we contacted the corresponding author up to three times by email with a request for access to the relevant data or the complete dataset. In addition, the GRADE system was applied to each outcome to evaluate the quality of evidence [17].

Two authors performed the risk of bias assessment independently with the Cochrane Risk of Bias 2 tool [18]. Meta-analysis was then performed with RevMan 5.4.1 (Nordic Cochrane Center, the Cochrane Collaboration). A meta-analysis was conducted if two or more trials reported the same outcome of interest. The  $I^2$  coefficient was used to assess heterogeneity with predetermined thresholds for low (25–49%); intermediate (50–74%); and high (75%) heterogeneity. A random effects model was used in case of intermediate or high heterogeneity; otherwise, a fixed effects model was used. To account for sources of heterogeneity, subgroup analyses were conducted for our primary outcomes according to the dose of intrathecal morphine (1–100 µg, 101–200 µg, 201–500 µg and > 500 µg); type of surgery (cardiothoracic, abdominal, gynaecological, orthopaedic and spine and other); and the anaesthetic strategy (general vs. spinal anaesthesia). When trials investigated multiple doses of morphine, data from each group were included in the relevant dose category.


We then performed trial sequential analysis for the three outcomes to control type 1 and type 2 errors, which can be affected by analysing data at multiple time-points (TSA software version 0.9.5.10 Beta;

Copenhagen Trial Unit, Copenhagen, Denmark). We calculated the Z-statistic with the DerSimonian and Laird random effects model. We set risks of type 1 and type 2 statistical errors at 5% and 20%, respectively, resulting in a power of 80%. The O'Brien Fleming alpha-spending function was used to adjust the threshold for statistical significance. The required information size was estimated following the incidences in the control and intrathecal morphine groups. The risk of publication bias associated with each of our primary outcomes was estimated by drawing a funnel plot of the rate of complication (y axis) as a function of the odds ratio (OR) of the complication (x-axis) [19]. This was then confirmed with Duval and Tweedie's trim and fill test [20]. This assessment was performed using Comprehensive Meta-analysis version 2 (Biostat, Englewood, NJ, USA).

We explored the potential correlation between the dose of intrathecal morphine and the risk of sedation, respiratory depression and hypoxaemia. For each

complication and each study, we computed an OR using Haldane-Anscombe correction in case of zero cells. Due to the positive skewness of these ORs, we considered their logarithm (logOR) and we built regression models with logOR as the outcome and the dose as the predictor [21]. Each study was weighted according to the variance of logOR. We started with linear regression and checked if more complex models using fractional polynomials or restricted cubic splines might improve the goodness of fit [22].

We conducted sensitivity analyses eliminating studies with a high risk of bias; restricting to doses of intrathecal morphine  $\leq 500 \mu\text{g}$ ; and both. To assess whether prolonged postoperative ventilation in certain trials, such as those involving cardiac surgery, could represent a confounding factor in the meta-analysis, we also conducted a sensitivity analysis after discounting trials using postoperative mechanical ventilation. These analyses were performed with Stata 18.0 (StataCorp, College Station, TX, USA). A



**Figure 1** Study flow diagram of literature search results.

**Table 1** Sedation reported in included studies investigating intrathecal morphine, analysed according to dose, type of surgery and anaesthetic strategy.

|                        | Number of trials | References   | Number of patients |          | Odds ratio (95%CI) | I <sup>2</sup> | p value for overall effects | p value for subgroup differences |
|------------------------|------------------|--|--------------------|----------|--------------------|----------------|-----------------------------|----------------------------------|
|                        |                  |  | Morphine           | Control  |                    |                |                             |                                  |
| Morphine dose          |                  |  |                    |          |                    |                |                             |                                  |
| 1–100 µg               | 17               | [38, 61, 62, 66, 67, 69, 74–76, 81, 88, 90, 92, 102, 106, 113, 114]                            | 46/499             | 37/456   | 1.08 (0.65–1.78)   | 2%             | 0.77                        | 0.01                             |
| 101–200 µg             | 16               | [32, 39, 62, 67, 75, 81, 88–90, 92, 106, 109, 113, 114, 117, 139]                              | 50/363             | 19/341   | 2.59 (1.49–4.48)   | 52%            | < 0.001                     |                                  |
| 201–500 µg             | 17               | [31, 34, 40, 51, 58, 75, 78, 82, 84, 88, 95, 97, 104, 117, 126, 128, 129]                      | 110/394            | 123/402  | 0.87 (0.62–1.22)   | 0%             | 0.42                        |                                  |
| 501–4000 µg            | 7                | [29, 49, 64, 78, 104, 135, 137]  | 28/184             | 19/127   | 0.91 (0.47–1.75)   | 0%             | 0.78                        |                                  |
| Surgery                |                  |  |                    |          |                    |                |                             |                                  |
| Cardiothoracic         | 4                | [29, 95, 97, 137]  | 21/84              | 22/73    | 1.00 (0.51–1.98)   | 0%             | 0.34                        | 0.30                             |
| Abdominal              | 8                | [31, 32, 34, 39, 40, 51, 58, 84]   | 65/224             | 75/225   | 0.79 (0.52–1.22)   | 2%             | 0.29                        |                                  |
| Gynaecological         | 4                | [74, 75, 82, 92]   | 47/176             | 36/97    | 0.93 (0.52–1.66)   | 11%            | 0.80                        |                                  |
| Orthopaedic and spinal | 22               | [38, 61, 62, 64, 66, 67, 76, 78, 88–90, 102, 106, 109, 113, 114, 117, 126, 128, 129, 135, 139] | 99/823             | 48/531   | 1.38 (0.91–2.11)   | 30%            | 0.13                        |                                  |
| Other                  | 4                | [49, 69, 81, 104]  | 2/133              | 0/99     | 2.35 (0.23–23.75)  | 0%             | 0.47                        |                                  |
| Anaesthetic strategy   |                  |  |                    |          |                    |                |                             |                                  |
| General anaesthesia    | 22               | [29, 31, 32, 34, 39, 40, 51, 58, 64, 75, 78, 82, 84, 90, 92, 95, 97, 117, 129, 135, 137, 139]  | 158/719            | 137/527  | 0.92 (0.69–1.23)   | 5%             | 0.58                        | 0.33                             |
| Spinal anaesthesia     | 30               | [38, 49, 61, 62, 66, 67, 69, 74, 76, 81, 88, 89, 102, 104, 106, 109, 113, 114, 126, 128]       | 76/721             | 44/498   | 1.21 (0.76–1.93)   | 23%            | 0.42                        |                                  |
| Total                  | 42               |  | 234/1440           | 181/1025 | 1.00 (0.78–1.28)   | 9%             | 0.98                        |                                  |

two-sided p value < 0.01 was deemed to be significant to correct for multiple comparisons.

## Results

We identified 3193 trials and 127 met the inclusion criteria [23–149] (Fig. 1), including a total of 7388 patients. The risk of bias of included trials is summarised in online Supporting Information Figure S1. Thirty-one authors were contacted [23, 24, 28, 33–35, 39, 41, 52, 58, 59, 62, 63, 68, 74, 75, 77, 81–83, 95, 96, 103, 110, 123, 135, 138, 143, 144, 147, 149] and seven provided additional data [23, 39, 74, 103, 110, 138, 144].

Among the 127 trials of intrathecal morphine, 25 (20%) were performed on patients having cardiothoracic surgery [24, 28, 29, 37, 41, 44–47, 53, 57, 77, 95, 97, 101, 116, 119,

120, 124, 132–134, 136, 137, 143]; 15 (12%) having abdominal surgery [31, 32, 34, 39, 40, 51, 55, 58, 59, 84, 85, 96, 123, 141, 146]; 15 (12%) having gynaecological surgery [25, 35, 43, 65, 70, 74, 75, 82, 83, 87, 92, 121, 122, 125, 145]; and 60 (47%) on patients undergoing orthopaedic and spine surgery [23, 26, 30, 33, 36, 38, 42, 48, 50, 52, 54, 56, 61–64, 66–68, 71–73, 76, 78–80, 88–90, 93, 94, 98–100, 102, 103, 106, 108–111, 113–115, 117, 126–131, 135, 138–140, 142, 144, 147–149] (online Supporting Information Table S1). Twelve (9%) trials assessed patients having other types of surgery [27, 49, 60, 69, 81, 86, 91, 104, 105, 107, 112, 118]. Authors used intrathecal morphine with doses ranging from 35 µg [127] to 4000 µg [29, 45, 124].

Tables 1–3 present rates of sedation, respiratory depression and hypoxaemia after intrathecal morphine

**Table 2** Respiratory depression reported in included studies investigating intrathecal morphine, analysed according to dose, type of surgery and anaesthetic strategy.

|                       | Number of trials | References  | Number of patients |         | Odds ratio (95%CI) | I <sup>2</sup> | p value for overall effects | p value for subgroup differences |
|-----------------------|------------------|---|--------------------|---------|--------------------|----------------|-----------------------------|----------------------------------|
|                       |                  |   | Morphine           | Control |                    |                |                             |                                  |
| Morphine dose         |                  |   |                    |         |                    |                |                             |                                  |
| 1–100 µg              | 35               | [43, 56, 61, 62, 66–69, 74–76, 81, 85–88, 90, 92, 100, 102, 103, 106, 112–115, 118, 121, 122, 138, 141, 142, 147–149]   | 12/1014            | 8/906   | 1.36 (0.60–3.06)   | 0%             | 0.46                        | 0.05                             |
| 101–200 µg            | 27               | [32, 39, 42, 62, 67, 68, 70, 75, 81, 86, 88–90, 92, 106, 107, 109, 113–115, 117, 122, 125, 137–139, 141]  | 26/685             | 8/644   | 2.68 (1.26–5.73)   | 0%             | 0.01                        |                                  |
| 201–500 µg            | 35               | [24, 26, 27, 31, 34–37, 40, 51, 53, 54, 57, 59, 71, 72, 75, 78, 83, 84, 88, 91, 94, 97, 104, 115–117, 119–121, 128, 129, 136, 144]  | 25/871             | 22/821  | 1.02 (0.55–1.89)   | 30%            | 0.96                        |                                  |
| 501–4000 µg           | 10               | [49, 64, 65, 78, 98, 101, 104, 124, 134, 143]   | 30/233             | 7/200   | 3.40 (1.62–7.13)   | 27%            | 0.001                       |                                  |
| Surgery               |                  |   |                    |         |                    |                |                             |                                  |
| Cardiothoracic        | 14               | [24, 37, 53, 57, 97, 101, 116, 119, 120, 124, 134, 136, 137, 143]   | 6/315              | 12/304  | 0.39 (0.13–1.23)   | 63%            | 0.11                        | 0.02                             |
| Abdominal             | 10               | [31, 32, 34, 39, 40, 51, 59, 84, 85, 141]   | 14/403             | 1/285   | 4.11 (0.87–19.36)  | 0%             | 0.07                        |                                  |
| Gynaecological        | 12               | [35, 43, 65, 70, 74, 75, 83, 87, 92, 121, 122, 125]   | 28/494             | 12/303  | 1.30 (0.62–2.71)   | 0%             | 0.48                        |                                  |
| Orthopaedic and spine | 38               | [26, 36, 42, 54, 56, 61, 62, 64, 66–68, 71, 72, 76, 78, 88–90, 94, 98, 100, 102, 103, 106, 109, 113–115, 117, 128, 129, 138, 139, 142, 144, 147–149]                      | 38/1316            | 8/921   | 2.39 (1.25–4.57)   | 0%             | 0.008                       |                                  |
| Other                 | 10               | [27, 49, 69, 81, 86, 91, 104, 107, 112, 118]  | 7/275              | 0/214   | 8.36 (1.06–66.29)  | 35%            | 0.04                        |                                  |
| Anaesthetic strategy  |                  |   |                    |         |                    |                |                             |                                  |
| General anaesthesia   | 39               | [24, 31, 32, 34, 35, 37, 39, 40, 51, 53, 57, 59, 64, 75, 78, 83, 84, 90, 92, 97, 101, 107, 116, 117, 119–121, 124, 125, 129, 134, 136, 137, 139, 141, 143, 144, 147, 149] | 55/1187            | 18/893  | 1.63 (0.91–2.91)   | 36%            | 0.10                        | 0.66                             |
| Spinal anaesthesia    | 45               | [26, 27, 36, 42, 43, 49, 54, 56, 61, 62, 65–72, 74, 76, 81, 85–89, 91, 94, 98, 100, 102–104, 106, 109, 112–115, 118, 122, 128, 138, 142, 148]                             | 38/1616            | 15/1134 | 1.95 (1.12–3.39)   | 0%             | 0.02                        |                                  |
| Total                 | 84               |   | 93/2803            | 33/2027 | 1.78 (1.19–2.67)   | 8%             | 0.005                       |                                  |

injection with subgroup analyses. Forest plots of these outcomes are shown in online Supporting Information Figures S2–S4. There were no significant differences between intrathecal morphine and control in the OR (95% CI) of sedation (1.00 (0.78–1.28),  $p = 0.98$ ) or hypoxaemia (1.22 (0.84–1.79),  $p = 0.30$ ). The quality of evidence was deemed moderate for both outcomes (online Supporting Information Table S2). Subgroup analysis according to dose revealed a significant increased rate of sedation with doses

of 101–200 µg, but not in the other dose subgroups. There were more episodes of respiratory depression in patients receiving intrathecal morphine than control (OR (95%CI) 1.78 (1.19–2.67),  $p = 0.005$ ), with very low-quality evidence (online Supporting Information Table S2). **Sensitivity analyses omitting studies at high risk of bias and/or restricted to doses of  $\leq 500$  µg showed no significant association between intrathecal morphine and control in the OR of sedation, hypoxaemia and respiratory depression**

**Table 3** Hypoxaemia reported in included studies investigating intrathecal morphine analysed according to dose, type of surgery and anaesthetic strategy.

|                       | Number of trials | References  | Number of patients |         | Odds ratio (95%CI)  | I <sup>2</sup> | p value for overall effects | p value for subgroup differences |
|-----------------------|------------------|---|--------------------|---------|---------------------|----------------|-----------------------------|----------------------------------|
|                       |                  |   | Morphine           | Control |                     |                |                             |                                  |
| Morphine dose         |                  |   |                    |         |                     |                |                             | 0.22                             |
| 1–100 µg              | 10               | [43, 90, 92, 100, 106, 115, 118, 121, 138, 142]             | 31/230             | 27/195  | 0.92 (0.48–1.73)    | 11%            | 0.79                        |                                  |
| 101–200 µg            | 8                | [23, 89, 90, 92, 106, 115, 138, 139]                        | 34/181             | 29/181  | 1.30 (0.70–2.40)    | 66%            | 0.40                        |                                  |
| 201–500 µg            | 12               | [35, 40, 48, 51, 53, 78, 83, 97, 99, 115, 121, 126]         | 49/263             | 39/264  | 1.27 (0.77–2.11)    | 0%             | 0.35                        |                                  |
| 501–4000 µg           | 1                | [78]  | 6/12               | 0/8     | 17.00 (0.80–359.81) | N/A            | 0.07                        |                                  |
| Surgery               |                  |   |                    |         |                     |                |                             | 0.33                             |
| Cardiothoracic        | 2                | [53, 97]  | 1/43               | 1/56    | 1.13 (0.07–18.73)   | N/A            | 0.93                        |                                  |
| Abdominal             | 2                | [40, 51]  | 10/70              | 15/70   | 0.50 (0.18–1.42)    | N/A            | 0.19                        |                                  |
| Gynaecological        | 5                | [35, 43, 83, 92, 121]                                       | 14/133             | 5/82    | 1.20 (0.39–3.71)    | 0%             | 0.75                        |                                  |
| Orthopaedic and spine | 13               | [23, 48, 78, 89, 90, 99, 100, 106, 115, 126, 138, 139, 142] | 95/412             | 39/282  | 1.46 (0.93–2.29)    | 48%            | 0.10                        |                                  |
| Other                 | 1                | [118]   | 0/28               | 0/14    | N/A                 | N/A            | N/A                         |                                  |
| Anaesthetic strategy  |                  |   |                    |         |                     |                |                             | 0.75                             |
| General anaesthesia   | 12               | [35, 40, 48, 51, 53, 78, 83, 90, 92, 97, 121, 139]          | 38/347             | 24/269  | 1.13 (0.61–2.10)    | 5%             | 0.70                        |                                  |
| Spinal anaesthesia    | 11               | [23, 43, 89, 99, 100, 106, 115, 118, 126, 138, 142]         | 82/339             | 36/235  | 1.28 (0.79–2.08)    | 56%            | 0.31                        |                                  |
| Total                 | 23               |   | 120/686            | 60/504  | 1.22 (0.84–1.79)    | 34%            | 0.30                        |                                  |

NA, not applicable.

(online Supporting Information Table S3). Meta-regression revealed an association between dose and rate of sedation, respiratory depression and hypoxaemia (Fig. 2). However, this effect appeared to be driven by very large doses given in earlier studies and restricting to a range now used commonly in clinical practice ( $\leq 500$  µg), these associations were no longer present (online Supporting Information Figures S5–S7). Sensitivity analysis which did not include patients who underwent postoperative ventilation did not alter the findings of our primary analyses (online Supporting Information Table S3).

Low-quality evidence suggested that there was no difference in the need for additional oxygen administration, the need for opioid antagonist administration, additional respiratory support or an escalated level of care (Table 4). No deaths were reported.


Trial sequential analyses reported that insufficient evidence has been reached for sedation and hypoxaemia, but sufficient evidence has been reached for statistical significance for respiratory depression (see online Supporting Information Figures S8–S10).

With respect to the risk of publication bias for the rate for sedation, Duval and Tweedie's trim and fill test

calculated the combined studies point estimate (95%CI) to be 0.90 (0.69–1.18) with a random-effects model. Using trim and fill, the imputed point estimate was 0.75 (0.55–1.01), suggesting that 10 studies were missing. For respiratory depression, Duval and Tweedie's trim and fill test calculated the combined studies point estimate (95%CI) to be 1.58 (1.01–2.46) with a random-effects model. Using trim and fill, the imputed point estimate was 1.12 (0.70–1.81), suggesting that nine studies were missing. Finally, for hypoxaemia, the combined studies point estimate (95%CI) was 1.52 (1.29–1.78) with a random-effects model. Using trim and fill, the imputed point estimate was 1.26 (1.06–1.51), suggesting that 20 studies were missing. Funnel plots are shown in online Supporting Information Figure S11.

## Discussion

This systematic review establishes that intrathecal morphine does not increase rates of sedation and hypoxaemia with a moderate level of evidence. Whilst our primary analyses showed that intrathecal morphine was associated with respiratory depression with a very low level of evidence, this association was not apparent in several sensitivity analyses,



**Figure 2** Meta-regression with linear model of (a) sedation; (b) respiratory depression; and (c) hypoxaemia according to the dose of intrathecal morphine. Red lines, linear regression; blue circles, observed values in each study.

nor did it persist with doses used in routine clinical practice ( $\leq 500 \mu\text{g}$ ). Meta-regression analyses showed an association between sedation, respiratory depression and hypoxaemia and the dose of morphine. This association did not persist when restricting to doses  $\leq 500 \mu\text{g}$ . However, as this threshold was set arbitrarily, the actual threshold might differ. That said, the  $500 \mu\text{g}$  threshold was defined based on the maximum dose administered typically in contemporary clinical practice. Interestingly, there was no increased need for oxygen therapy, antagonism of opioids or any additional respiratory support or escalated levels of care. Additionally, no trials reported any mortality. Finally, the type of surgery or anaesthetic strategy did not impact the results.

The lack of a clear association between typical intrathecal morphine doses and pulmonary complications deserves to be considered. While there might be no true association, another explanation might be the pulmonary

effects of systemic opioids administered in patients who did not receive intrathecal morphine and who may have developed moderate-to-severe postoperative pain. Pulmonary complications in these patients might eliminate differences observed in patients receiving intrathecal morphine. Data showing a difference in pulmonary outcomes comparing systemic opioids and intrathecal administration are required.

Concerns regarding the risk of respiratory depression also warrant further consideration. In our primary analysis, there appears to be a significant difference in outcome. However, when high doses of intrathecal morphine were not included, this difference was no longer significant. The trial sequential analysis suggested that sufficient information had been reached; however, the GRADE quality of evidence undermines this confidence, as does a more critical assessment of the outcome. Adding to this, respiratory depression usually warrants treatment with either antagonism of opioids or treatment with additional oxygen therapy or respiratory support, but our results show no evidence of increased requirement in these additional treatments. This could be caused by high-risk studies not detecting or reporting additional support, or by the fact that there were variable definitions of respiratory depression, some of which may not require such interventions.

This meta-analysis has several limitations. The lack of continuous monitoring to measure respiratory depression or hypoxaemia in some of the trials could have led to underreporting of potential events. Another limitation was the variability in definitions applied across trials for each of our three outcomes. For instance, regarding respiratory depression, trials used cut-off values including  $< 6$ ,  $8$ ,  $10$  and  $13 \text{ breaths} \cdot \text{min}^{-1}$ . However, consistent with the equipoise principle, we do not consider this limitation to affect the validity of our results significantly. That said, we urge researchers to perform prospective dose-safety trials of intrathecal morphine for each of these complications in specific surgeries and populations, with consistent definitions, to confirm the results of this meta-analysis. Although we initially registered on PROSPERO that we aimed to include other hydrophilic opioids such as hydromorphone or diamorphine, we focused this meta-analysis on intrathecal morphine given the volume of evidence and the difficulty with comparing other drugs [7]. As the safety profile of these opioids might possibly diverge from morphine, future research in this area is needed, especially with head-to-head comparisons between hydrophilic opioids, to determine whether one molecule for the intrathecal administration should be favoured in clinical practice. Some of the subgroup and sensitivity analyses



**Table 4** Secondary outcomes reported in included studies investigating intrathecal morphine.

| Outcome   | Number of trials | References   | Number of patients |         | Odds ratio (95%CI) | I <sup>2</sup> | p value for overall effects |
|---|------------------|--|--------------------|---------|--------------------|----------------|-----------------------------|
|   |                  |  | Morphine           | Control |                    |                |                             |
| Need for oxygenation  | 12               | [42, 48, 51, 61, 68, 71, 72, 88, 99, 113, 115, 116]                            | 41/468             | 27/391  | 1.31 (0.74–2.30)   | 22%            | 0.35                        |
| Need for opioid antagonist  | 19               | [34–36, 41, 42, 52, 64, 68, 72, 75, 79, 84, 101, 109, 113, 121, 124, 136, 149] | 5/793              | 1/565   | 1.94 (0.52–7.32)   | 0%             | 0.33                        |
| Need for any additional respiratory support or escalated levels of care | 13               | [24, 34, 35, 37, 52–54, 66, 68, 77, 119, 120, 149]                             | 3/482              | 4/404   | 0.85 (0.20–3.59)   | 0%             | 0.82                        |

were not pre-registered, as their completion became necessary during the analysis and review processes to refine our results. Finally, we did not include observational studies, which may provide invaluable evidence in the setting of intrathecal morphine and pulmonary outcomes [150].

In conclusion, there is moderate evidence that intrathecal morphine does not increase rates of sedation or hypoxaemia after all types of non-obstetric surgery, though more data may be needed. There was evidence of an association between intrathecal morphine and respiratory depression, but this association did not persist in the range of doses used commonly in contemporary clinical practice. Intrathecal morphine does not appear to influence the need for oxygenation, administration of opioid antagonists or the need for any additional respiratory support or escalated levels of care. Variability in outcome definitions warrants caution when translating these results into clinical practice. These findings could inform future clinical guidelines and management.

## Author affiliations

Kariem El-Boghdadly,<sup>1,2</sup> Yves Renard,<sup>3</sup> Jean-Benoit Rossel,<sup>4</sup> Eleni Moka,<sup>5</sup> Thomas Volk,<sup>6</sup> Narinder Rawal,<sup>7</sup> Cécile Jaques,<sup>8</sup> Marta Szyzsko,<sup>3</sup> and Eric Albrecht,<sup>3</sup>

1 Department of Anaesthesia, Guy's and St Thomas' NHS Foundation Trust, London, UK  
 2 King's College London, London, UK  
 3 Department of Anaesthesia, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland  
 4 Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland  
 5 Department of Anaesthesia, Creta Interclinic Hospital, Hellenic Healthcare Group, Heraklion-Crete, Greece

6 Department of Anaesthesia, Intensive Care and Pain Therapy, Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg, Germany  
 7 Institute of Clinical Medicine, Örebro University, Örebro, Sweden  
 8 Medical Library, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

## Acknowledgements

This study was registered on PROSPERO (CRD42023387850) and supported by the European Society of Regional Anaesthesia and Pain Therapy. KE is an Editor of *Anaesthesia*. KE or his institution received grant, educational or travel funding from Ambu, GE Healthcare, Fisher and Paykel and Edwards Life Sciences unrelated to this work. EM has received honoraria from Menarini and Menarini Hellas. EA received grants from the Swiss Academy for Anaesthesia Research, Lausanne, Switzerland (no grant numbers attributed) and from the Swiss National Science Foundation to support his clinical research. Data and statistical code are not available. No other funding or competing interests are declared.

## References

1. Grape S, El-Boghdadly K, Albrecht E. Management of adverse effects of intrathecal opioids in acute pain. *Best Pract Res Clin Anaesthesiol* 2023; **37**: 199–207. <https://doi.org/10.1016/j.bpa.2023.02.002>.
2. Wang JK, Nauss LA, Thomas JE. Pain relief by intrathecally applied morphine in man. *Anesthesiology* 1979; **50**: 149–51. <https://doi.org/10.1097/0000542-197902000-00013>.
3. Koning MV, Teunissen AJW, van der Harst E, Ruijgrok EJ, Stolker RJ. Intrathecal morphine for laparoscopic segmental colonic resection as part of an enhanced recovery protocol: a randomized controlled trial. *Reg Anesth Pain Med* 2018; **43**: 166–73. <https://doi.org/10.1097/AAP.0000000000000703>.
4. Gonvers E, El-Boghdadly K, Grape S, Albrecht E. Efficacy and safety of intrathecal morphine for analgesia after lower joint arthroplasty: a systematic review and meta-analysis with



- meta-regression and trial sequential analysis. *Anaesthesia* 2021; **76**: 1648–58. <https://doi.org/10.1111/anae.15569>.
5. Pirie K, Myles PS, Riedel B. A survey of neuraxial analgesic preferences in open and laparoscopic major abdominal surgery amongst anaesthetists in Australia and New Zealand. *Anaesth Intensive Care* 2020; **48**: 314–7. <https://doi.org/10.1177/0310057x20937315>.
  6. Pirie K, Doane MA, Riedel B, Myles PS. Analgesia for major laparoscopic abdominal surgery: a randomised feasibility trial using intrathecal morphine. *Anaesthesia* 2022; **77**: 428–37. <https://doi.org/10.1111/anae.15651>.
  7. Grape S, El-Boghdadly K, Jaques C, Albrecht E. Efficacy and safety of intrathecal diamorphine: a systematic review and meta-analysis with meta-regression and trial sequential analysis. *Anaesthesia* 2024; **79**: 1081–90. <https://doi.org/10.1111/anae.16359>.
  8. Bailey PL, Lu JK, Pace NL, et al. Effects of intrathecal morphine on the ventilatory response to hypoxia. *N Engl J Med* 2000; **343**: 1228–34. <https://doi.org/10.1056/nejm200010263431705>.
  9. Meylan N, Elia N, Lysakowski C, Tramèr MR. Benefit and risk of intrathecal morphine without local anaesthetic in patients undergoing major surgery: meta-analysis of randomized trials. *Br J Anaesth* 2009; **102**: 156–67. <https://doi.org/10.1093/bja/aen368>.
  10. Bai JW, Singh M, Short A, et al. Intrathecal morphine and pulmonary complications after arthroplasty in patients with obstructive sleep apnea: a retrospective cohort study. *Anesthesiology* 2020; **132**: 702–12. <https://doi.org/10.1097/ALN.0000000000003110>.
  11. Koning MV, Klimek M, Rijs K, Stolker RJ, Heesen MA. Intrathecal hydrophilic opioids for abdominal surgery: a meta-analysis, meta-regression, and trial sequential analysis. *Br J Anaesth* 2020; **125**: 358–72. <https://doi.org/10.1016/j.bja.2020.05.061>.
  12. Raft J, Podrez K, Baumann C, Richebe P, Bouaziz H. Postoperative clinical monitoring after morphine administration: a retrospective multicenter practice survey. *Curr Drug Saf* 2019; **14**: 140–6. <https://doi.org/10.2174/1574886314666190306110434>.
  13. National Institute for Health and Care Excellence. Caesarean birth: monitoring after intrathecal or epidural opioids for caesarean birth: evidence review. [NG192]. <https://www.nice.org.uk/guidance/ng192/evidence/e-monitoring-after-intrathecal-or-epidural-opioids-for-caesarean-birth-pdf-9071941650> (accessed 11/03/2025).
  14. Rawal N. Intrathecal opioids for the management of post-operative pain. *Best Pract Res Clin Anaesthesiol* 2023; **37**: 123–32. <https://doi.org/10.1016/j.bpa.2023.01.001>.
  15. Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. *BMJ* 2021; **372**: n160. <https://doi.org/10.1136/bmj.n160>.
  16. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. Press peer review of electronic search strategies: 2015 guideline statement. *J Clin Epidemiol* 2016; **75**: 40–6. <https://doi.org/10.1016/j.jclinepi.2016.01.021>.
  17. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol* 2011; **64**: 401–6. <https://doi.org/10.1016/j.jclinepi.2010.07.015>.
  18. Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019; **366**: l4898. <https://doi.org/10.1136/bmj.l4898>.
  19. Carlisle JB. Systematic reviews: how they work and how to use them. *Anaesthesia* 2007; **62**: 702–7. <https://doi.org/10.1111/j.1365-2044.2007.05092.x>.
  20. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 2000; **56**: 455–63. <https://doi.org/10.1111/j.0006-341x.2000.00455>.
  21. Hamza T, Furukawa TA, Orsini N, Cipriani A, Salanti G. Dose-effect meta-analysis for psychopharmacological interventions using randomised data. *Evid Based Ment Health* 2022; **25**: 1–6. <https://doi.org/10.1136/ebmental-2021-300278>.
  22. Hamza T, Furukawa TA, Orsini N, Cipriani A, Iglesias CP, Salanti G. A dose-effect network meta-analysis model with application in antidepressants using restricted cubic splines. *Stat Methods Med Res* 2024; **33**: 1461–72. <https://doi.org/10.1177/09622802211070256>.
  23. Albrecht E, Bayon V, Hirotsu C, Al Ja'bari A, Heinzer R. Intrathecal morphine and sleep apnoea severity in patients undergoing hip arthroplasty: a randomised, controlled, triple-blinded trial. *Br J Anaesth* 2020; **125**: 811–7. <https://doi.org/10.1016/j.bja.2020.07.052>.
  24. Alhashemi JA, Sharpe MD, Harris CL, Sherman V, Boyd D. Effect of subarachnoid morphine administration on extubation time after coronary artery bypass graft surgery. *J Cardiothorac Vasc Anesth* 2000; **14**: 639–44. <https://doi.org/10.1053/jcan.2000.18300>.
  25. Almeida RA, Lauretti GR, Mattos AL. Antinociceptive effect of low-dose intrathecal neostigmine combined with intrathecal morphine following gynecologic surgery. *Anesthesiology* 2003; **98**: 495–8. <https://doi.org/10.1097/0000542-200302000-00031>.
  26. Altunkaya H, Ozer Y, Demirel CB, Ozkocak I, Keser S, Bayar A. Preoperative multimodal administration of morphine in arthroscopic surgery. *Arch Orthop Trauma Surg* 2005; **125**: 609–13. <https://doi.org/10.1007/s00402-004-0788-9>.
  27. Amanor-Boadu SD. Assessment of minidose intrathecal morphine for analgesia after hemorrhoidectomy. *West Afr J Med* 1992; **11**: 146–9.
  28. Askar FZ, Kocabas S, Yucel S, Samancilar O, Cetin H, Uyar M. The efficacy of intrathecal morphine in post-thoracotomy pain management. *J Int Med Res* 2007; **35**: 314–22. <https://doi.org/10.1177/14732323000703500305>.
  29. Aun C, Thomas D, St. John-Jones L, Colvin MP, Savege TM, Lewis CT. Intrathecal morphine in cardiac surgery. *Eur J Anaesthesiol* 1984; **2**: 419–26.
  30. Bachmann M, Laakso E, Niemi L, Rosenberg PH, Pitkanen M. Intrathecal infusion of bupivacaine with or without morphine for postoperative analgesia after hip and knee arthroplasty. *Br J Anaesth* 1997; **78**: 666–70. <https://doi.org/10.1093/bja/78.6.666>.
  31. Ban M, Choi YS, Koo BN. Analgesic effect of intrathecal morphine combined with low-dose bupivacaine on postoperative analgesia after liver resection: a randomized controlled study. *J Pers Med* 2022; **12**: 211. <https://doi.org/10.3390/jpm12020211>.
  32. Bang YJ, Lee EK, Kim CS, et al. The effect of intrathecal morphine on postoperative opioid consumption in patients undergoing abdominal surgery for gynecologic malignancy: a randomized sham-controlled trial. *Anesth Analg* 2023; **137**: 525–33. <https://doi.org/10.1213/ANE.0000000000006358>.
  33. Barrington JW, Emerson RH, Lovald ST, Lombardi AV, Berend KR. No difference in early analgesia between liposomal bupivacaine injection and intrathecal morphine after tka. *Clin Orthop Relat Res* 2017; **475**: 94–105. <https://doi.org/10.1007/s11999-016-4931-z>.
  34. Beaussier M, Weickmans H, Parc Y, et al. Postoperative analgesia and recovery course after major colorectal surgery in elderly patients: a randomized comparison between intrathecal morphine and intravenous pca morphine. *Reg Anesth Pain Med* 2006; **31**: 531–8. <https://doi.org/10.1016/j.rapm.2006.06.250>.
  35. Beltrutti D, Niv D, Ben-Abraham R, Di Santo S, Weinbroum AA. Late antinociception and lower untoward effects of

- concomitant intrathecal morphine and intravenous buprenorphine in humans. *J Clin Anesth* 2002; **14**: 441–6. [https://doi.org/10.1016/s0952-8180\(02\)00397-5](https://doi.org/10.1016/s0952-8180(02)00397-5).
36. Bengtsson M, Lofstrom JB, Merits H. Postoperative pain relief with intrathecal morphine after major hip surgery. *Reg Anesth* 1983; **8**: 139–43. <https://doi.org/10.1136/rapm-00115550-198308040-00001>.
  37. Bhat I, Arya VK, Mandal B, Jayant A, Dutta V, Rana SS. Postoperative hemodynamics after high spinal block with or without intrathecal morphine in cardiac surgical patients: a randomized-controlled trial. *Can J Anaesth* 2021; **68**: 825–34. <https://doi.org/10.1007/s12630-021-01937-z>.
  38. Biswas A, Perlas A, Ghosh M, et al. Relative contributions of adductor canal block and intrathecal morphine to analgesia and functional recovery after total knee arthroplasty: a randomized controlled trial. *Reg Anesth Pain Med* 2018; **43**: 154–60. <https://doi.org/10.1097/AAP.0000000000000724>.
  39. Blay M, Orban JC, Rami L, et al. Efficacy of low-dose intrathecal morphine for postoperative analgesia after abdominal aortic surgery: a double-blind randomized study. *Reg Anesth Pain Med* 2006; **31**: 127–33. <https://doi.org/10.1016/j.rapm.2005.11.010>.
  40. Boonmak S, Boonmak P, Bunsangjaroen P, Srichaipanha S, Thinchellong V. Comparison of intrathecal morphine plus pca and pca alone for post-operative analgesia after kidney surgery. *J Med Assoc Thai* 2007; **90**: 1143–9.
  41. Boulanger A, Perreault S, Choiniere M, Prieto I, Lavoie C, Laflamme C. Intrathecal morphine after cardiac surgery. *Ann Pharmacother* 2002; **36**: 1337–43. <https://doi.org/10.1345/aph.1A477>.
  42. Brunschweiler M, Van Gessel E, Forster A, Bruce A, Gamulin Z. Comparison of clonidine, morphine or placebo mixed with bupivacaine during continuous spinal anaesthesia. *Can J Anaesth* 1998; **45**: 735–40. <https://doi.org/10.1007/BF03012143>.
  43. Campbell DC, Riben CM, Rooney ME, Crone LA, Yip RW. Intrathecal morphine for postpartum tubal ligation postoperative analgesia. *Anesth Analg* 2001; **93**: 1006–11. <https://doi.org/10.1097/0000539-200110000-00042>.
  44. Casey WF, Wynands JE, Ralley FE, et al. The role of intrathecal morphine in the anesthetic management of patients undergoing coronary artery bypass surgery. *J Cardiothorac Anesth* 1987; **1**: 510–6. [https://doi.org/10.1016/0888-6296\(87\)90036-6](https://doi.org/10.1016/0888-6296(87)90036-6).
  45. Chaney MA, Smith KR, Barclay JC, Slogoff S. Large-dose intrathecal morphine for coronary artery bypass grafting. *Anesth Analg* 1996; **83**: 215–22. <https://doi.org/10.1097/0000539-199608000-00003>.
  46. Chaney MA, Furry PA, Fluder EM, Slogoff S. Intrathecal morphine for coronary artery bypass grafting and early extubation. *Anesth Analg* 1997; **84**: 241–8. <https://doi.org/10.1097/0000539-199702000-00002>.
  47. Chaney MA, Nikolov MP, Blakeman BP, Bakhos M. Intrathecal morphine for coronary artery bypass graft procedure and early extubation revisited. *J Cardiothorac Vasc Anesth* 1999; **13**: 574–8. [https://doi.org/10.1016/s1053-0770\(99\)90010-1](https://doi.org/10.1016/s1053-0770(99)90010-1).
  48. Cole PJ, Craske DA, Wheatley RG. Efficacy and respiratory effects of low-dose spinal morphine for postoperative analgesia following knee arthroplasty. *Br J Anaesth* 2000; **85**: 233–7. <https://doi.org/10.1093/bja/85.2.233>.
  49. Cunningham AJ, McKenna JA, Skene DS. Single injection spinal anaesthesia with amethocaine and morphine for transurethral prostatectomy. *Br J Anaesth* 1983; **55**: 423–7. <https://doi.org/10.1093/bja/55.5.423>.
  50. Demiraran Y, Yucel I, Akcali GE, Degirmenci E, Sezen G, Iskender A. Adding intrathecal morphine to unilateral spinal anesthesia results in better pain relief following knee arthroscopy. *J Anesth* 2008; **22**: 367–72. <https://doi.org/10.1007/s00540-008-0648-9>.
  51. Devys JM, Mora A, Plaud B, et al. Intrathecal + PCA morphine improves analgesia during the first 24 hr after major abdominal surgery compared to pca alone. *Can J Anaesth* 2003; **50**: 355–61. <https://doi.org/10.1007/BF03021032>.
  52. Dhaliwal P, Yavin D, Whittaker T, et al. Intrathecal morphine following lumbar fusion: a randomized, placebo-controlled trial. *Neurosurgery* 2019; **85**: 189–98. <https://doi.org/10.1093/neuros/nyy384>.
  53. Dhawan R, Daubenspeck D, Wroblewski KE, et al. Intrathecal morphine for analgesia in minimally invasive cardiac surgery: a randomized, placebo-controlled, double-blinded clinical trial. *Anesthesiology* 2021; **135**: 864–76. <https://doi.org/10.1097/ALN.0000000000003963>.
  54. Drakeford MK, Pettine KA, Brookshire L, Ebert F. Spinal narcotics for postoperative analgesia in total joint arthroplasty. A prospective study. *J Bone Joint Surg Am* 1991; **73**: 424–8.
  55. Düger C, Mimaroglu C, Kaygusuz K, Kol IO, Gürsoy S. The investigation of the effects of morphine on qt interval at spinal anesthesia with bupivacaine. *Anestezi Derg* 2008; **16**: 196–200.
  56. Eichler F, Decker T, Muller E, Kasper SM, Rutt J, Grond S. [Efficacy and safety of 0.1 mg of intrathecal morphine in arthroscopic knee joint surgery]. *Schmerz* 2004; **18**: 515–9. <https://doi.org/10.1007/s00482-003-0294-y>.
  57. Elgendy H, Helmy HAR. Intrathecal morphine improves hemodynamic parameters and analgesia in patients undergoing aortic valve replacement surgery: a prospective, double-blind, randomized trial. *Pain Physician* 2017; **20**: 405–12.
  58. El-Rahman AM, Mohamed AA, Mohamed SA, Mostafa MAM. Effect of intrathecally administered ketamine, morphine, and their combination added to bupivacaine in patients undergoing major abdominal cancer surgery: a randomized, double-blind study. *Pain Med* 2018; **19**: 561–8. <https://doi.org/10.1093/pm/pnx105>.
  59. El Sherif FA, Othman AH, Abd El-Rahman AM, Taha O. Effect of adding intrathecal morphine to a multimodal analgesic regimen for postoperative pain management after laparoscopic bariatric surgery: a prospective, double-blind, randomized controlled trial. *Br J Pain* 2016; **10**: 209–16. <https://doi.org/10.1177/2049463716668904>.
  60. Fader JP, Cleary RK, Lampman RM, Winter S, Singal BM, Plona AE. Does intrathecal morphine sulfate provide preemptive analgesia for patients undergoing stapled hemorrhoidopexy? *Pain Med* 2011; **12**: 322–7. <https://doi.org/10.1111/j.1526-4637.2010.01042.x>.
  61. Fenten MG, Keijzer BA, Stienstra R. No clinically relevant advantage of intrathecal morphine in total hip arthroplasty? *Acta Anaesthesiol Belg* 2014; **65**: 161–6.
  62. Foadi N, Karst M, Frese-Gaul A, Rahe-Meyer N, Kromer S, Weilbach C. The improved quality of postoperative analgesia after intrathecal morphine does not result in improved recovery and quality of life in the first 6 months after orthopedic surgery: a randomized controlled pilot study. *J Pain Res* 2017; **10**: 1059–69. <https://doi.org/10.2147/JPR.S135142>.
  63. Fogarty DJ, Carabine UA, Milligan KR. Comparison of the analgesic effects of intrathecal clonidine and intrathecal morphine after spinal anaesthesia in patients undergoing total hip replacement. *Br J Anaesth* 1993; **71**: 661–4. <https://doi.org/10.1093/bja/71.5.661>.
  64. France JC, Jorgenson SS, Lowe TG, Dwyer AP. The use of intrathecal morphine for analgesia after posterolateral lumbar fusion: a prospective, double-blind, randomized study. *Spine* 1997; **22**: 2272–7. <https://doi.org/10.1097/00007632-199710010-00015>.

65. Gallegos-Allier MM, Santacruz L, Lomelí J. Postoperative analgesic effect with single microdose versus intrathecal morphine preparation of intravenous ketorolac gynecological surgery. *Rev Mex Anestesiol* 2012; **35**: 15–9.
66. Gehling M, Tryba M, Lusebrink T, Zorn A. [Can the addition of clonidine improve the analgesic efficacy of low dose intrathecal morphine? A randomised double-blind trial]. *Anaesthesist* 2003; **52**: 204–9. <https://doi.org/10.1007/s00101-003-0459-1>.
67. Gehling M, Tryba M. [Intrathecal morphine in orthopaedic surgery patients. Optimised dose in patients receiving dipyrone]. *Anaesthesist* 2008; **57**: 347–54. <https://doi.org/10.1007/s00101-008-1341-y>.
68. Gehling MH, Luesebrink T, Kulka PJ, Tryba M. The effective duration of analgesia after intrathecal morphine in patients without additional opioid analgesia: a randomized double-blind multicentre study on orthopaedic patients. *Eur J Anaesthesiol* 2009; **26**: 683–8. <https://doi.org/10.1097/EJA.0b013e328329b045>.
69. Goel S, Lal S, Goyal R. A comparison of post operative analgesia and adverse effects produced by neostigmine and morphine when given intrathecally. *Indian J Public Health Res Dev* 2012; **3**: 154–7.
70. Goyagi T, Nishikawa T. The addition of epinephrine enhances postoperative analgesia by intrathecal morphine. *Anesth Analg* 1995; **81**: 508–13. <https://doi.org/10.1097/0000539-199509000-00014>.
71. Grace D, Milligan KR, Morrow BJ, Fee JP. Co-administration of pethidine and clonidine: a spinal anaesthetic technique for total hip replacement. *Br J Anaesth* 1994; **73**: 628–33. <https://doi.org/10.1093/bja/73.5.628>.
72. Grace D, Bunting H, Milligan KR, Fee JP. Postoperative analgesia after co-administration of clonidine and morphine by the intrathecal route in patients undergoing hip replacement. *Anesth Analg* 1995; **80**: 86–91. <https://doi.org/10.1097/0000539-199501000-00015>.
73. Gurkan Y, Canatay H, Ozdamar D, Solak M, Toker K. Spinal anesthesia for arthroscopic knee surgery. *Acta Anaesthesiol Scand* 2004; **48**: 513–7. <https://doi.org/10.1111/j.1399-6576.2004.00353.x>.
74. Habib AS, Muir HA, White WD, Spahn TE, Olufolabi AJ, Breen TW, Duke Women's Anesthesia Research Group. Intrathecal morphine for analgesia after postpartum bilateral tubal ligation. *Anesth Analg* 2005; **100**: 239–43. <https://doi.org/10.1213/01.ANE.0000143955.37182.09>.
75. Hein A, Rosblad P, Gillis-Haegerstrand C, Schedvins K, Jakobsson J, Dahlgren G. Low dose intrathecal morphine effects on post-hysterectomy pain: a randomized placebo-controlled study. *Acta Anaesthesiol Scand* 2012; **56**: 102–9. <https://doi.org/10.1111/j.1399-6576.2011.02574.x>.
76. Hur MJ, Kim YJ, Baik H, Kim JH. Effect of intrathecal morphine for total knee replacement arthroplasty elderly patients. *Korean J Anesthesiol* 2007; **52**: 172–8. <https://doi.org/10.4097/kjae.2007.52.2.172>.
77. Jacobsohn E, Lee TW, Amadeo RJ, et al. Low-dose intrathecal morphine does not delay early extubation after cardiac surgery. *Can J Anaesth* 2005; **52**: 848–57. <https://doi.org/10.1007/BF03021781>.
78. Jacobson L, Chabal C, Brody MC. A dose-response study of intrathecal morphine: efficacy, duration, optimal dose, and side effects. *Anesth Analg* 1988; **67**: 1082–8.
79. Johnson A, Bengtsson M, Soderlind K, Lofstrom JB. Influence of intrathecal morphine and naloxone intervention on postoperative ventilatory regulation in elderly patients. *Acta Anaesthesiol Scand* 1992; **36**: 436–44. <https://doi.org/10.1111/j.1399-6576.1992.tb03493.x>.
80. Kaczocha M, Azim S, Nicholson J, et al. Intrathecal morphine administration reduces postoperative pain and peripheral endocannabinoid levels in total knee arthroplasty patients: a randomized clinical trial. *BMC Anesthesiol* 2018; **18**: 27. <https://doi.org/10.1186/s12871-018-0489-5>.
81. Kamath SS, Hosagoudar P, Ambareesha. Comparison of efficacy of intrathecal morphine 100 µg and 200 µg for postoperative pain relief in patients undergoing lower abdominal and lower limb surgeries. *J Anaesthesiol Clin Pharmacol* 2009; **25**: 63–5.
82. Kara I, Apiliogullari S, Oc B, et al. The effects of intrathecal morphine on patient-controlled analgesia, morphine consumption, postoperative pain and satisfaction scores in patients undergoing gynaecological oncological surgery. *J Int Med Res* 2012; **40**: 666–72. <https://doi.org/10.1177/147323001204000229>.
83. Karaman S, Kocabas S, Uyar M, Zincircioglu C, Firat V. Intrathecal morphine: effects on perioperative hemodynamics, postoperative analgesia, and stress response for total abdominal hysterectomy. *Adv Ther* 2006; **23**: 295–306. <https://doi.org/10.1007/BF02850135>.
84. Kim HC, Bae JY, Kim TK, et al. Efficacy of intrathecal morphine for postoperative pain management following open nephrectomy. *J Int Med Res* 2016; **44**: 42–53. <https://doi.org/10.1177/0300060515595650>.
85. Kip G, Akçabay M. Comparison of the use of different doses of intrathecal morphine added to levobupivacaine for spinal anaesthesia during unilateral inguinal hernia repair. *Gazi Med J* 2017; **30**: 21–7.
86. Kirson LE, Goldman JM, Slover RB. Low-dose intrathecal morphine for postoperative pain control in patients undergoing transurethral resection of the prostate. *Anesthesiology* 1989; **71**: 192–5. <https://doi.org/10.1097/0000542-198908000-00004>.
87. Klamt JG, Slullitel A, Garcia IV, Prado WA. Postoperative analgesic effect of intrathecal neostigmine and its influence on spinal anaesthesia. *Anaesthesia* 1997; **52**: 547–51. <https://doi.org/10.1111/j.1365-2222.1997.115-az0111.x>.
88. Kunopart M, Chanthong P, Thongpolswat N, Itiyanaravut T, Pethuahong C. Effects of single shot femoral nerve block combined with intrathecal morphine for postoperative analgesia: a randomized, controlled, dose-ranging study after total knee arthroplasty. *J Med Assoc Thai* 2014; **97**: 195–202.
89. Kwan AS, Lee BB, Brake T. Intrathecal morphine for postoperative analgesia in patients with fractured hips. *Hong Kong Med J* 1997; **3**: 250–5.
90. Kwon HU, Kim SH, Lim YS, Kang PS. Postoperative analgesic effect of combined low dose intrathecal morphine and continuous epidural opioid local anesthetic mixture after lumbar laminectomy. *Korean J Pain* 2004; **17**: 217–21. <https://doi.org/10.3344/jkps.2004.17.2.217>.
91. Lanz E, Daublander M, Lipp M, Theiss D. 0.5 mg intrathecal morphine in spinal anesthesia. A double blind study on sensory block, postoperative analgesia and adverse effects. *Reg Anesth* 1984; **7**: 79–85.
92. Lauretti GR, Reis MP, Prado WA, Klamt JG. Dose-response study of intrathecal morphine versus intrathecal neostigmine, their combination, or placebo for postoperative analgesia in patients undergoing anterior and posterior vaginoplasty. *Anesth Analg* 1996; **82**: 1182–7. <https://doi.org/10.1097/0000539-199606000-00014>.
93. Lauretti GR, Righeti CC, Mattos AL. Intrathecal ketorolac enhances intrathecal morphine analgesia following total knee arthroplasty. *J Anaesthesiol Clin Pharmacol* 2013; **29**: 503–8. <https://doi.org/10.4103/0970-9185.119155>.
94. Lee ES, Kim TY, Yoon JS. Effect of intrathecal morphine on tourniquet pain. *Korean J Anesthesiol* 1990; **23**: 424–9. <https://doi.org/10.4097/kjae.1990.23.3.424>.
95. Lena P, Balarac N, Arnulf JJ, Teboul J, Bonnet F. Intrathecal morphine and clonidine for coronary artery bypass grafting. *Br*

- J Anaesth* 2003; **90**: 300–3. <https://doi.org/10.1093/bja/aeg070>.
96. Licina MG, Schubert A, Tobin JE, Nicodemus HF, Spitzer L. Intrathecal morphine does not reduce minimum alveolar concentration of halothane in humans: results of a double-blind study. *Anesthesiology* 1991; **74**: 660–3. <https://doi.org/10.1097/0000542-199104000-00007>.
  97. Liu N, Kuhlman G, Dalibon N, Moutafis M, Levron JC, Fischler M. A randomized, double-blinded comparison of intrathecal morphine, sufentanil and their combination versus iv morphine patient-controlled analgesia for postthoracotomy pain. *Anesth Analg* 2001; **92**: 31–6. <https://doi.org/10.1097/0000539-200101000-00007>.
  98. Lydon AM, Cooke T, Duggan F, Shorten GD. Delayed postoperative gastric emptying following intrathecal morphine and intrathecal bupivacaine. *Can J Anaesth* 1999; **46**: 544–9. <https://doi.org/10.1007/BF03013544>.
  99. Machino M, Yukawa Y, Hida T, Oka Y, Terashima T, Kinoshita S, Kato F. A prospective randomized study for postoperative pain relief of lower extremity fractures: efficacy of intrathecal morphine administration. *Nagoya J Med Sci* 2010; **72**: 145–50.
  100. Matsuda M, Ueki R, Murakawa K, Sasaki K, Boo K, Tashiro C. [Low dose intrathecal morphine and postoperative pain relief in elderly patients]. *Masui* 2001; **50**: 1096–100.
  101. Mehta Y, Kulkarni V, Juneja R, et al. Spinal (subarachnoid) morphine for off-pump coronary artery bypass surgery. *Heart Surg Forum* 2004; **7**: E205–10. <https://doi.org/10.1532/HSF98.20033014>.
  102. Mendieta Sanchez JM, Fernandez-Liesa JL, Marco G, Panadero A, Sanchez-Ledesma MJ, Macias A. Efficacy of 0.1 mg of subarachnoid morphine combined with bupivacaine on postoperative analgesia in total hip arthroplasty. *Rev Esp Anesthesiol Reanim* 1999; **46**: 433–7.
  103. Miyamoto S, Sugita T, Aizawa T, et al. The effect of morphine added to periarticular multimodal drug injection or spinal anesthesia on pain management and functional recovery after total knee arthroplasty. *J Orthop Sci* 2018; **23**: 801–6. <https://doi.org/10.1016/j.jos.2018.04.013>.
  104. Mora C, Dupuis JL, Feiss P. Spinal anesthesia and morphine analgesia in prostatic surgery. *Cah Anesthesiol* 1985; **33**: 25–7.
  105. Moreira H Jr, Moreira JP, Isaac RR, Alves-Neto O, Moreira TA, Vieira TH, Brasil AM. Morphine spinal block anesthesia in patients who undergo an open hemorrhoidectomy: a prospective analysis of pain control and postoperative complications. *Ann Coloproctol* 2014; **30**: 135–40. <https://doi.org/10.3393/ac.2014.30.3.135>.
  106. Murphy PM, Stack D, Kinirons B, Laffey JG. Optimizing the dose of intrathecal morphine in older patients undergoing hip arthroplasty. *Anesth Analg* 2003; **97**: 1709–15. <https://doi.org/10.1213/01.ANE.0000089965.75585.0D>.
  107. Nuri Deniz M, Erhan E, Ugur G. Intrathecal morphine reduces postoperative tramadol consumption in patients undergoing radical retropubic prostatectomy: a randomized trial. *Eur Rev Med Pharmacol Sci* 2013; **17**: 834–8.
  108. O'Neill P, Knickenberg C, Bogahalanda S, Booth AE. Use of intrathecal morphine for postoperative pain relief following lumbar spine surgery. *J Neurosurg* 1985; **63**: 413–6. <https://doi.org/10.3171/jns.1985.63.3.0413>.
  109. Oberhofer D, Sakic K, Neseek-Adam V, et al. Low dose spinal morphine and intravenous diclofenac for postoperative analgesia after total hip and knee arthroplasty. *Period Biol* 2011; **113**: 191–6.
  110. Olive DJ, Barrington MJ, Simone SA, Kluger R. A randomised controlled trial comparing three analgesia regimens following total knee joint replacement: continuous femoral nerve block, intrathecal morphine or both. *Anaesth Intensive Care* 2015; **43**: 454–60. <https://doi.org/10.1177/0310057X1504300406>.
  111. Omara A, Amer AF. Effect of intrathecal morphine before and after laminectomy on intra-operative surgical stress response and post-operative pain: a prospective randomized study. *J Opioid Manag* 2019; **16**: 15–22. <https://doi.org/10.5055/jom.2020.0546>.
  112. Onk D, Akarsu Ayazoglu T, Kuyrukluylidiz U, et al. Effects of fentanyl and morphine on shivering during spinal anesthesia in patients undergoing endovenous ablation of varicose veins. *Med Sci Monit* 2016; **22**: 469–73. <https://doi.org/10.12659/msm.897256>.
  113. Park CK, Cho CK, Lee JH, Shin HH. Optimizing the dose of intrathecal morphine when combined with continuous 3-in-1 nerve block after total knee replacement. *Korean J Anesthesiol* 2009; **57**: 69–77. <https://doi.org/10.4097/kjae.2009.57.1.69>.
  114. Pathonsamit C, Onklin I, Hongku N, Chaiyakit P. Randomized double-blind controlled trial comparing 0.2 mg, 0.1 mg, and no intrathecal morphine combined with periarticular injection for unilateral total knee arthroplasty. *Arthroplast Today* 2021; **7**: 253–9. <https://doi.org/10.1016/j.artd.2020.11.008>.
  115. Rathmell JP, Pino CA, Taylor R, Patrin T, Viani BA. Intrathecal morphine for postoperative analgesia: a randomized, controlled, dose-ranging study after hip and knee arthroplasty. *Anesth Analg* 2003; **97**: 1452–7. <https://doi.org/10.1213/01.ANE.0000083374.44039.9E>.
  116. Roediger L, Joris J, Senard M, Larbuisson R, Canivet JL, Lamy M. The use of pre-operative intrathecal morphine for analgesia following coronary artery bypass surgery. *Anaesthesia* 2006; **61**: 838–44. <https://doi.org/10.1111/j.1365-2044.2006.04744.x>.
  117. Ross DA, Drasner K, Weinstein PR, Flaherty JF, Barbaro NM. Use of intrathecally administered morphine in the treatment of postoperative pain after lumbar spinal surgery: a prospective, double-blind, placebo-controlled study. *Neurosurgery* 1991; **28**: 700–4. <https://doi.org/10.1097/00006123-199105000-00010>.
  118. Sakai T, Use T, Shimamoto H, Fukano T, Sumikawa K. Mini-dose (0.05 mg) intrathecal morphine provides effective analgesia after transurethral resection of the prostate. *Can J Anaesth* 2003; **50**: 1027–30. <https://doi.org/10.1007/BF03018367>.
  119. Santos LM, Santos VC, Santos SR, Malbouisson LM, Carmona MJ. Intrathecal morphine plus general anesthesia in cardiac surgery: effects on pulmonary function, postoperative analgesia, and plasma morphine concentration. *Clinics (Sao Paulo)* 2009; **64**: 279–85. <https://doi.org/10.1590/s1807-59322009000400003>.
  120. Santos VCJ, Sanches-Giraud C, Lanchote VL, Santos LM, Carmona MJ, Santos SRCJ. PK/PD of morphine for postoperative analgesia after coronary artery bypass grafting. Intrathecal morphine significantly reduces drug consumption. *Lat Am J Pharm* 2012; **31**: 686–92.
  121. Sarma VJ, Bostrom UV. Intrathecal morphine for the relief of post-hysterectomy pain—a double-blind, dose-response study. *Acta Anaesthesiol Scand* 1993; **37**: 223–7. <https://doi.org/10.1111/j.1399-6576.1993.tb03705.x>.
  122. Satoh O, Hatakeyama Y, Miyazawa F, Tsumura T, Miyabe M, Namiki A. [Intrathecal morphine for postoperative pain relief after transvaginal hysterectomy]. *Masui* 1992; **41**: 1517–9.
  123. Schubert A, Licina MG, Lineberry PJ, Deers MA. The effect of intrathecal morphine on somatosensory evoked potentials in awake humans. *Anesthesiology* 1991; **75**: 401–5. <https://doi.org/10.1097/0000542-199109000-00004>.
  124. Sebel PS, Aun C, Fiolet J, Noonan K, Savege TM, Colvin MP. Endocrinological effects of intrathecal morphine. *Eur J Anaesthesiol* 1985; **2**: 291–6.
  125. Selvam V, Subramaniam R, Baidya DK, et al. Safety and efficacy of low-dose intrathecal morphine for laparoscopic



- hysterectomy: a randomized, controlled pilot study. *J Gynecol Surg* 2018; **34**: 77–83. <https://doi.org/10.1089/gyn.2017.0096>.
126. Sites BD, Beach M, Biggs R, et al. Intrathecal clonidine added to a bupivacaine-morphine spinal anesthetic improves postoperative analgesia for total knee arthroplasty. *Anesth Analg* 2003; **96**: 1083–8. <https://doi.org/10.1213/01.ANE.0000055651.24073.59>.
  127. Sundarathiti P, Thammasakulsiri J, Supboon S, Sakdanuwatwong S, Piangjai M. Comparison of continuous femoral nerve block (CFNB/SA) and continuous femoral nerve block with mini-dose spinal morphine (CFNB/SAMO) for postoperative analgesia after total knee arthroplasty (TKA): a randomized controlled study. *BMC Anesthesiol* 2016; **16**: 38. <https://doi.org/10.1186/s12871-016-0205-2>.
  128. Tan PH, Chia YY, Lo Y, Liu K, Yang LC, Lee TH. Intrathecal bupivacaine with morphine or neostigmine for postoperative analgesia after total knee replacement surgery. *Can J Anaesth* 2001; **48**: 551–6. <https://doi.org/10.1007/BF03016831>.
  129. Techanivate A, Kiatgungwanglia P, Yingsakmongkol W. Spinal morphine for post-operative analgesia after lumbar laminectomy with fusion. *J Med Assoc Thai* 2003; **86**: 262–9.
  130. Tomaszewski D, Balkota M, Truszczynski A, Machowicz A. Intrathecal morphine increases the incidence of urinary retention in orthopaedic patients under spinal anaesthesia. *Anaesthesiol Intensive Ther* 2014; **46**: 29–33. <https://doi.org/10.5603/AIT.2014.0006>.
  131. Tuominen M, Valli H, Kalso E, Rosenberg PH. Efficacy of 0.3 mg morphine intrathecally in preventing tourniquet pain during spinal anaesthesia with hyperbaric bupivacaine. *Acta Anaesthesiol Scand* 1988; **32**: 113–6. <https://doi.org/10.1111/j.1399-6576.1988.tb02697.x>.
  132. Turker G, Gören S, Sahin S, Korfali G, Sayan E. [Efficacy and safety of intrathecal morphine combined with remifentanyl anesthesia in beating heart coronary artery surgery]. *Anesth Yog Bak Dern Derg* 2004; **10**: 67–74.
  133. Turker G, Goren S, Sahin S, Korfali G, Sayan E. Combination of intrathecal morphine and remifentanyl infusion for fast-track anesthesia in off-pump coronary artery bypass surgery. *J Cardiothorac Vasc Anesth* 2005; **19**: 708–13. <https://doi.org/10.1053/j.jvca.2005.08.011>.
  134. Turkoz A, Soysal O, Togal T, et al. Intrathecal morphine prior to the thoracotomy. *Agri* 1999; **11**: 42–6.
  135. Urban MK, Jules-Elysee K, Urquhart B, Cammisa FP, Boachie-Adjiei O. Reduction in postoperative pain after spinal fusion with instrumentation using intrathecal morphine. *Spine Phila Pa* 2002; **27**: 535–7. <https://doi.org/10.1097/00007632-200203010-00015>.
  136. Vanstrum GS, Bjornson KM, Ilko R. Postoperative effects of intrathecal morphine in coronary artery bypass surgery. *Anesth Analg* 1988; **67**: 261–7.
  137. Vijitpavan A, Kittikunakorn N, Komonhirun R. Comparison between intrathecal morphine and intravenous patient control analgesia for pain control after video-assisted thoracoscopic surgery: a pilot randomized controlled study. *PLoS One* 2022; **17**: e0266324. <https://doi.org/10.1371/journal.pone.0266324>.
  138. Vitola E, Buraka N, Ertz R, Golubovska I, Miscuks A. Effect of different low doses of intrathecal morphine (0.1 and 0.2 mg) on pain and vital functions in patients undergoing total hip arthroplasty: a randomised controlled study. *BMC Anesthesiol* 2022; **22**: 377. <https://doi.org/10.1186/s12871-022-01919-8>.
  139. Wang Y, Guo X, Guo Z, Xu M. Preemptive analgesia with a single low dose of intrathecal morphine in multilevel posterior lumbar interbody fusion surgery: a double-blind, randomized, controlled trial. *Spine J* 2020; **20**: 989–97. <https://doi.org/10.1016/j.spinee.2020.03.001>.
  140. Weber EW, Slappendel R, Gielen MJ, Dirksen R. Intrathecal addition of morphine to bupivacaine is not the cause of postoperative nausea and vomiting. *Reg Anesth Pain Med* 1998; **23**: 81–6. [https://doi.org/10.1016/s1098-7339\(98\)90115-8](https://doi.org/10.1016/s1098-7339(98)90115-8).
  141. Yamaguchi H, Watanabe S, Motokawa K, Ishizawa Y. Intrathecal morphine dose-response data for pain relief after cholecystectomy. *Anesth Analg* 1990; **70**: 168. <https://doi.org/10.1213/00000539-199002000-00006>.
  142. Yamashita K, Fukusaki M, Ando Y, Tanabe T, Terao Y, Sumikawa K. Postoperative analgesia with minidose intrathecal morphine for bipolar hip prosthesis in extremely elderly patients. *J Anesth* 2009; **23**: 504–7. <https://doi.org/10.1007/s00540-009-0817-5>.
  143. Yapici D, Altunkan ZO, Atici S, et al. Postoperative effects of low-dose intrathecal morphine in coronary artery bypass surgery. *J Card Surg* 2008; **23**: 140–5. <https://doi.org/10.1111/j.1540-8191.2007.00566.x>.
  144. Yen D, Turner K, Mark D. Is a single low dose of intrathecal morphine a useful adjunct to patient-controlled analgesia for postoperative pain control following lumbar spine surgery? A preliminary report. *Pain Res Manag* 2015; **20**: 129–32. <https://doi.org/10.1155/2015/761390>.
  145. Yokota T, Uehara K, Nomoto Y. Addition of noradrenaline to intrathecal morphine augments the postoperative suppression of natural killer cell activity. *J Anesth* 2004; **18**: 190–5. <https://doi.org/10.1007/s00540-004-0247-3>.
  146. Yonemura E, Shimada M, Nakamura M, Fukushima K. Influence of intrathecal morphine and buprenorphine on EEG and their analgesic effect. *Jpn J Anesthesiol* 1990; **39**: 478–86.
  147. Yorukoglu D, Ates Y, Temiz H, Yamali H, Kecik Y. Comparison of low-dose intrathecal and epidural morphine and bupivacaine infiltration for postoperative pain control after surgery for lumbar disc disease. *J Neurosurg Anesthesiol* 2005; **17**: 129–33. <https://doi.org/10.1097/01.ana.0000167146.13415.7c>.
  148. Yue L, Zhang F, Mu G, Shang M, Lin Z, Sun H. Effectiveness and safety of intrathecal morphine for percutaneous endoscopic lumbar discectomy under low-dose ropivacaine: a prospective, randomized, double-blind clinical trial. *Spine J* 2023; **23**: 954–61. <https://doi.org/10.1016/j.spinee.2023.03.001>.
  149. Ziegeler S, Fritsch E, Bauer C, et al. Therapeutic effect of intrathecal morphine after posterior lumbar interbody fusion surgery: a prospective, double-blind, randomized study. *Spine Phila Pa* 2008; **33**: 2379–86. <https://doi.org/10.1097/BRS.0b013e3181844ef2>.
  150. Duggan LV, El-Boghdady K. The importance of prospective observational studies in airway management: yet only the first step. *Anaesthesia* 2021; **76**: 1555–8. <https://doi.org/10.1111/anae.15538>.

## Supporting Information

Additional supporting information may be found online via the journal website.

**Figure S1.** Cochrane Risk of Bias 2 summary.

**Figure S2.** Forest plot for sedation.

**Figure S3.** Forest plot for respiratory depression.

**Figure S4.** Forest plot for hypoxaemia.

**Figure S5.** Sensitivity analysis without high-risk studies.

**Figure S6.** Sensitivity analysis with doses of  $\leq 500$   $\mu\text{g}$  only.

**Figure S7.** Sensitivity analysis without high-risk studies and doses of  $\leq 500$   $\mu\text{g}$  only.

**Figure S8.** Trial sequential analysis for rate of sedation.

**Figure S9.** Trial sequential analysis for rate of respiratory depression.

**Figure S10.** Trial sequential analysis for rate of hypoxaemia.

**Figure S11.** Funnel plot for (a) sedation; (b) respiratory depression; and (c) hypoxaemia according to the dose of intrathecal morphine.

**Table S1.** Characteristics of studies included in this study.

**Table S2.** Quality of evidence assessment for each primary outcome with intrathecal morphine.

**Table S3.** Sensitivity analyses.

**Appendix S1.** Literature search strategy.